News >

O'Brien Shares Overview of CLL Sequencing

Brandon Scalea
Published: Friday, Aug 10, 2018

Susan M. O’Brien, MD

Susan M. O'Brien, MD
Chemotherapy is becoming less of a priority in the treatment paradigm of chronic lymphocytic leukemia (CLL) with the addition of the FDA-approved novel agents ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta), explained Susan M. O’Brien, MD.

For example, data have strongly indicated that patients with CLL who have a 17p deletion will not respond to chemotherapy. Chimeric antigen receptor (CAR) T-cell therapy could be an alternative for these patients in an early setting, O’Brien said.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication